INTRODUCTION 37
Despite the progress recently made in tuberculosis (TB) control at a global level, the decline in 38 TB incidence is much slower than that needed to achieve TB elimination by 2050 [1] . 39
Identifying and treating symptom-free people who are truly latently infected with 40
M.tuberculosis (Mtb) is key to achieving this[2][3]. The current global burden of latent 41
infection is uncertain, although it has been suggested that one third of the world's population 42 may be latently infected with Mtb [4] . 43
Although they show no sign of disease, individuals with latent tuberculosis infection (LTBI) 44 are at risk of reactivating and up to 10% of them may develop active disease in their lifetime [5] . 45
This risk is highest in the first 2 years following infection. Preventive treatment of recently-46 infected individuals reduces this [6] . However isoniazid preventive therapy is not optimal for a 47 large-scale implementation program, and the current LTBI diagnostic tests -Tuberculin Skin 48
Test (TST) and Interferon- release assay (IGRAs)-have significant limitations. TST may be 49
falsely positive due to sensitization by environmental mycobacteria and BCG-vaccination [7] . 50
In recent decades IGRAs measuring the INF- concentration after in vitro whole blood 51 stimulation with peptides from the RD-1 region of the Mtb genome were developed to improve 52 specificity of the diagnosis [8] . IGRAs are a useful indicator of Mtb exposure as their specificity 53 is very high (97%) [9] . However, like TST, they lose sensitivity in immune-compromised 54 individuals and children [10] [11]; they identify both recent and past infection and they are poor 55 at predicting LTBI subjects who are at greater risk of developing disease (positive predictive 56 value IGRA 2,7% TST 1,5%) [12] . As a result when currently available diagnostic tests are used 57 to guide the administration of preventive therapy, the number needed to treat to prevent one 58 case of TB is too high to allow a large-scale preventive program. Different approaches have 59 been described in the literature to help discriminate those at greater risk of active TB 60 development. The use of INF- response to the latency antigen Heparin-Binding-61 independent of their response to QTF, have a greater CD8 + T cell response compared to other 80 study groups (active TB patients, health care workers, BCG-vaccinated healthy controls) [24] . 81 This is in agreement with findings observed in a cattle model where a CD8 + T cell response is 82 present at the onset of infection. [25] 83
The INF- release assays currently in use primarily elicit a CD4 + response, but emerging data 84 provide a good rationale for also measuring specific CD8 + T cell responses and in particular 85 to further investigate the association between CD8 + T cells and risk of disease progression. 86
In the present study we evaluate the performance characteristics of the new QFT-Plus assay in 87
TST-positive contacts with recent exposure to people with confirmed active tuberculosis, 88 assessing the use of QFT-Plus head-to-head with the previous QFT-GIT. In addition, we 89 investigate for the first time the significance and the possible use of the CD8 + INF- response 90 provided by the second newly-added antigen tube. 91
92

MATERIAL AND METHOD 93
Study setting and participants 94
We conducted a cross-sectional study at Villa Marelli-Niguarda Hospital. TB incidence in 95 disease, HIV, malignancy, immunosuppressive medications) were included. 104
The study was approved by the Ethics committee 
Statistical Analysis 138
The agreement between QFT-GIT and QFT-Plus was evaluated by computing the overall 139 percent of concordant results and Cohen's kappa coefficient with 95% Confidence Interval (CI). 140
Univariate logistic regression and backward stepwise multivariate logistic regression models 141 were used to identify factors associated with positive test results. The variables considered in 142 the analyses were: gender, whether the country of birth was an endemic area of TB and whether 143 it was European, BCG vaccination, immunocompromised status, smear status of index case, 144 average time spent per week with the index case and place of sleeping with respect to the index 145 case. The same analysis was performed for the variable denoting whether the differences 146 between QFT-Plus TB2 and QFT-Plus TB1 was greater than the cut-off 0.6 IU/ml (as described 147 in the Results). The level of significance considered was 5%. All statistical analyses were done 148 using R statistical software (version 3.2.3). 149
150
RESULTS
151
A total of 119 Mtb-exposed individuals with positive TST (5mm) were investigated. Of these, 152 39 were contacts of a smear-negative culture-positive TB case, and 69 of a smear-positive 153 culture positive index case. Participants had a median age of 38 years (25-75 percentile: 30-154 79), more than half (n=61, 51.26%) were non-European-born, 82 (78.85%) were BCG-155 vaccinated and 11 (9.24%) were immunocompromised subjects. Demographic characteristics 156 of the cohort are shown in the Table 1 . 157
Agreement between QFT-Plus and QFT-GIT 158
Sixty-eight out of 119 (57.1%) contacts were QFT-Plus positive. 64 subjects were positive in 159 both antigen tubes, 2 were positive to TB1 only and 2 were positive to TB2 only. Fifty-six of 160 119 TST-positive contacts were positive to QFT-GIT. The overall agreement between the two 161
IGRAs was high, with a Cohen's kappa of 0.8 (95% CI 0.69-0.91). The two tests gave 162 concordant results for 107 (89.9%) subjects (see Table 2 ). Discordant results were found in 12 163 subjects: they all scored negative to the QFT-GIT and positive to the QFT-Plus. Discordant 164 results between the two IGRAs included the 4 contacts with a single tube QFT-Plus positivity.low to be considered borderline results (median: TB1-Nil=0.83 IU/ml, TB2-Nil=0.73 IU/ml). 167
The characteristics of subjects with discordant results are shown in Table 3 . Only one of the 12 168 contacts with QFT-Plus positive and QFT-GIT negative results had a TST response less than 169 10mm (7mm). Globally, the median TB1 QFT-Plus antigen IFN-γ level (TB1-Nil) was 0.74 170 IU/ml, whereas the median TB2 QFT-Plus antigen IFN-γ level (TB2-Nil) was 0.67 IU/ml, as 171 reported in Table 2 . 172
As per the Italian guidelines, contacts of TB cases with initial positive TST results who tested 173 negative to a first QFT-GIT analysis, were re-tested with QFT-GIT at 10-12 weeks. At the post-174 exposure follow-up, two contacts converted to QFT-GIT positive results. Both of them were 175 part of the 12 contacts who initially showed QFT-plus-positive/QFT-GIT-negative discordant 176 results ( Table 2 ). One of them had a strong QFT-GIT positivity (>10 ml/IU) at 10 weeks post-177 exposure follow-up; while the second case reported a QFT-GIT of 0.5 ml/UI after 6 month of 178 isoniazid preventive therapy (decision to treat was based on the strong TST positivity and the 179 proximity of contact with the index case). In both cases the TB2 INF- response was greater 180 than that found in TB1. 181
Independent predictors of QFT-Plus and QFT-GIT positivity 182
For both QFT-GIT and QFT Plus test, the univariate odds ratios of being positive for different 183 possible surrogate markers of increasing exposure to Mtb is presented in Table 4 . Contacts 184 reporting that they had spent more than 12 hours per day with the index case were significantly 185 more likely to be both QFT-GIT and QFT-Plus positive, compared to contacts spending 1-4 186 hours per day with the index case. For a subject with an exposure time > 12 hours, the odds of 187 a positive test were 6 times higher by QFT-GIT and 14 times higher by QFT-Plus. Both test 188 results were significantly more likely to be positive in subjects with closer sleeping proximity (15.13%) had a difference between TB2 and TB1 greater than 0.6 IU/ml. Univariate logistic 205 regression was used to identify factors associated with differences between TB2 and TB1 > 0.6 206 IU/ml (Table 4 ). This method identified sleeping in the same room compared to sleeping in 207 different houses (OR: 4.34; 95%CI: 1.37-13.81), and European origin (OR: 3.24; 95%CI: 1.07-208 9.75) to be to be significantly positively associated with a greater TB2 response. These 209 associations persisted in the multivariate analysis, shown in Table 6 . positive/QFT-GIT negative contacts was in the majority of cases out of the uncertainty zone 218 for test interpretation [29] , suggesting that differences between the tests are not due to test 219 variability. Of note, the disagreement between the two tests all goes in the same direction, with 220 a total of 12 TST-positive contacts positive with the new QFT-Plus and negative to QFT-GIT. 221
With no gold standard for LTBI to refer to, it is difficult to assess whether the discordant results 222 found during the contact screening are attributable to the higher sensitivity of the QFT-Plus 223 test. If the TST were taken as the reference test for LTBI, this would mean that the proportion 224 of TST-positive contacts confirmed by the IGRA test is increased by 17% when using the QFT-225
Plus compared to QFT-GIT. False positivity with TST is mainly due to sensitization by BCG-226 vaccination [7] . QFT-Plus specificity in a BCG-vaccinated population has not been investigated 227 yet, however we found that QFT-Plus is not associated with BCG-vaccination both in univariate 228 and multivariate analysis. Moreover only one of the 12 contacts with QFT-Plus positive and 229 QFT-GIT negative result had a TST response less than 10mm while another showed an intense 230 TST positivity which is less likely to be the result of previous vaccination [7] study we find that most of the discordant cases (QFT-GIT negative/QFT-Plus positive) show 234 intense TST positivity; moreover, we reported a shorter period of conversion for QFT-Plus 235 compared to QFT-GIT at least in two individuals of our cohort. These results suggest that QFT-236
Plus may be more sensitive in detecting new or recent infection with Mtb than the QFT-GIT. 237
Our data demonstrate that risk factors for test positivity were the same for both IGRAs. QFT-238
Plus showed stronger associations with surrogate measure of recent exposure than QFT-GIT 239 both in univariate and multivariate analysis The average time spent per day with the index case 240 had the strongest association with test positivity. 241
We investigated for the first time the difference in INF- production between the two QFT-Plus 242 tubes and surrogate markers of increasing exposure. TB2-TB1 differential values were used as 243 an indirect estimate of specific CD8
+ stimulation with the newly added antigens. A cut-off value 244 was set at 0.6 ml /IU in order to exclude small variations due to inter-test variability [29] . [34], suggesting that the presence of CD8 + T cells in a small proportion of latently infected 267 individuals may be predictive of Mtb active replication and more likely disease progression [22] . 268
Consistent with these results, in a previous study we found that the difference in responses 269 between the QFT-Plus tubes may positively correlate with increasing antigenic load in active 270 TB patients, as it was significantly more common in smear-positive versus smear-negative 271 active TB patients [35] . In the present study, we observed a greater TB2 antigen response (TB2-272 TB1 difference >0.6ml/UI) in 18 (15.13%) individuals, all QFT-Plus positive. We speculate 273 that the small subgroup of latently infected contacts with TB2-TB1 difference >0.6ml/UI have 274 higher antigenic burden. However, to date, we do not have the tools to directly assess Mtb 275
antigenic burden, as current LTBI tests rely on the (indirect) measurement of a specific immune 276
response. 277
Our study has limitations. The foremost of these was the sample size, which comprises 119 278 subjects. Moreover because of the lack of gold standard tests for LTBI, we were unable to 279 adequately resolve the discordance between QFT-GIT and QFT-Plus. In addition, TST-280 negative contacts were not recruited in our sample and a full evaluation of the test would benefit 281 of their presence. Finally, the positive predictive value of the test and of the new parameter, the 282 difference between the two antigen tubes, needs to be properly assessed in a longitudinal cohort. 283
However, this would require follow-up of a large cohort (as incident TB is an uncommon event) 284 and could only be performed in groups who are not eligible for chemoprophylaxis. 285
To our knowledge, our study is the first evaluation of QFT-Plus assay among recent contacts 286 of TB cases. Although limited by the small sample size, our data show that QFT-Plus in contact 287 screening has an improved performance compared to QFT-GIT and suggests a role for the 288 differential value between the two tubes as a proxy for recent infection. Larger prospective 289 studies are needed to assess the positive predictive value of the test and the possible role of the 290 differential value between the two antigens tube as marker for recent infection. 291
In conclusion, the difference between the two antigen tubes, used as an indirect estimate of 292 specific CD8 + activation, is associated with factors indicating increased Mtb exposure, 293
suggesting that this might identify individuals at greater risk of progression to active TB. 
Table1: Demographic characteristics
